699 32 Olyaei A, De Mattos A, Bennett W Prescribing drugs in renal disease In Brenner B, editor The kidney Philadelphia WB Saunders; 2000 p 2606–53 33 Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB[.]
36 Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal… 32 Olyaei A, De Mattos A, Bennett W. Prescribing drugs in renal disease In: Brenner B, editor The kidney Philadelphia: WB Saunders; 2000 p. 2606–53 33 Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC) Prevention and control of influenza Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 2005;54(RR-8):1–40 Available from: http:// www.ncbi.nlm.nih.gov/pubmed/16086456 34 Chow-Tung E, Lau AH, Vidyasagar D, John EG. Effect of peritoneal dialysis on serum concentrations of three drugs commonly used in pediatric patients Dev Pharmacol Ther 1985;8(2):85–95 35 Lanao JM, Dominguez-Gil A, Tabernero JM, Macias J. Influence of type of dialyzer on the pharmacokinetics of amikacin Int J Clin Pharmacol Ther Toxicol 1983;21:197–202 36 Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration Crit Care Med 1990;18(6):675–6 Available from: http://www.ncbi nlm.nih.gov/pubmed/2344762 37 Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant J-Y, et al Influence of renal replacement modalities on amikacin population pharmacokinetics in critically Ill patients on continuous renal replacement therapy Antimicrob Agents Chemother 2016;60(8):4901–9 38 D’Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration BMC Pharmacol Toxicol 2012;13:14 39 Smeltzer BD, Schwartzman MS, Bertino JS. Amikacin pharmacokinetics during continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 1988;32(2):236–40 Available from: http://www.ncbi.nlm.nih.gov/pubmed/3364945 40 Oe PL, Simonian S, Verhoef J. Pharmacokinetics of the new penicillins Amoxycillin and flucloxacillin in patients with terminal renal failure undergoing haemodialysis Chemotherapy 1973;19(5):279–88 41 Bouman CSC. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration Curr Opin Crit Care 2008;14(6):654–9 42 Bouman CSC, Van Kan HJM, Koopmans RP, Korevaar JC, Schultz MJ, Vroom MB. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing Intensive Care Med 2006;32(12):2013–9 43 Hui K, Patel K, Kong DCM, Kirkpatrick CMJ. Impact of high-flux haemodialysis on the probability of target attainment for oral amoxicillin/clavulanic acid combination therapy Int J Antimicrob Agents 2017;50(1):110–3 699 44 Slaughter RL, Kohli R, Brass C. Effects of hemodialysis on the pharmacokinetics of amoxicillin/ clavulanic acid combination Ther Drug Monit 1984;6(4):424–7 45 Wan WTP, Guerra Valero Y, GYS C, Ordóđez Mejia JL, Wallis SC, Joynt GM, et al In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration Int J Antimicrob Agents 2019;54(2):261–4 46 Muther RS, Bennett WM. Peritoneal clearance of amphotericin B and 5-fluorocytosine West J Med 1980;133(2):157–60 Available from: http://www ncbi.nlm.nih.gov/pubmed/7015695 47 Block ER, Bennett JE, Livoti LG, Klein WJJ, MacGregor RR, Henderson L. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance Studies in man Ann Intern Med 1974;80(5):613–7 48 Malone ME, Corrigan OI, Kavanagh PV, Gowing C, Donnelly M, D’Arcy DM. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration Int J Antimicrob Agents 2013;42(4):335–42 49 Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno- venous haemofiltration Int J Antimicrob Agents 2004;23(1):80–3 Available from: http://www.ncbi nlm.nih.gov/pubmed/14732318 50 Cotterill S. Antimicrobial prescribing in patients on haemofiltration J Antimicrob Chemother 1995;36(5):773–80 Available from: http://www ncbi.nlm.nih.gov/pubmed/8626257 51 Jusko WJ, Lewis GP, Schmitt GW. Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects Clin Pharmacol Ther 1973;14:90–9 52 Golper TA, Pulliam J, Bennett WM. Removal of therapeutic drugs by continuous arteriovenous hemofiltration Arch Intern Med 1985;145(9):1651– Available from: http://www.ncbi.nlm.nih.gov/ pubmed/4026495 53 Kent JR, Almond MK, Dhillon S. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int 2001;21(4):372–7 54 Berman SJ, Boughton WH, Sugihara JG, Wong EG, Sato MM, Siemsen AW. Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis Antimicrob Agents Chemother 1978;14(3):281–3 55 Gartenberg G, Meyers BR, Hirschmann SZ, Srulevitch E. Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis J Antimicrob Chemother 1979;5(4):465–70 56 Spyker DA, Gober LL, Scheld WM, Sande MA, Bolton WK. Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis Antimicrob Agents Chemother 1982;21(2):278–81 57 Marx MA, Frye RF, Matzke GR, Golper TA. Cefazolin as empiric therapy in hemodialysis- 700 related infections: efficacy and blood concentrations Am J Kidney Dis 1998;32(3):410–4 58 Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients Perit Dial Int 2019;19(1):65–70 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/10201343 59 Manley HJ, Bridwell DL, Elwell RJ, Bailie GR. Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin Perit Dial Int 2019;23(5):469–74 Available from: http://www ncbi.nlm.nih.gov/pubmed/14604200 60 Sowinski KM, Mueller BA, Grabe DW, Manley HJ, Frye RF, Bailie GR, et al Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers Am J Kidney Dis 2001;37(4):766–76 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11273877 61 Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis Clin Pharmacol Ther 1983;33(1):66–72 Available from: http://www.ncbi nlm.nih.gov/pubmed/6848301 62 Cronqvist J, Nilsson-Ehle I, Oqvist B, Norrby SR. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment Antimicrob Agents Chemother 1992;36(12):2676–80 63 Wong KM, Chan WK, Chan YH, Li CS. Cefepime- related neurotoxicity in a haemodialysis patient Nephrol Dial Transplant 1999;14(9):2265–6 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/10489256 64 Barbhaiya RH, Knupp CA, Pfeffer M, Zaccardelli D, Dukes GM, Mattern W, et al Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 1992;36(7):1387–91 65 Carlier M, Taccone FS, Beumier M, Seyler L, Cotton F, Jacobs F, et al Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy Int J Antimicrob Agents 2015;46(4):413–9 Available from: https://linkinghub.elsevier.com/ retrieve/pii/S0924857915002265 66 Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL. Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients Clin Ther 2005;27(5):599–608 67 Faulkner RD, Yacobi A, Barone JS, Kaplan SA, Silber BM. Pharmacokinetic profile of cefixime in man Pediatr Infect Dis J 1987;6(10):963–70 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/3696837 68 Guay DR, Meatherall RC, Harding GK, Brown GR. Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency Antimicrob Agents Chemother 1986;30(3):485–90 B L Blowey et al 69 Albin H, Demotes-Mainard F, Bouchet J, Vincon G, Martin-Dupont C. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis Clin Pharmacol Ther 1985;38:285–9 70 Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function Rev Infect Dis 2019;4(Suppl):S379–91 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/6294787 71 Höffler D, Koeppe P, Corcilius M, Przyklinik A. Cefpodoxime proxetil in patients with end- stage renal failure on hemodialysis Infection 2019;18(3):157–62 Available from: http://www ncbi.nlm.nih.gov/pubmed/2365467 72 Borin MT, Hughes GS, Kelloway JS, Shapiro BE, Halstenson CE. Disposition of cefpodoxime proxetil in hemodialysis patients J Clin Pharmacol 1992;32(11):1038–44 Available from: http://www ncbi.nlm.nih.gov/pubmed/1474165 73 Johnson CA, Ateshkadi A, Zimmerman SW, Hughes GS, Craig WA, Carey PM, et al Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 1993;37(12):2650–5 74 Shyu WC, Pittman KA, Wilber RB, Matzke GR, Barbhaiya RH. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment J Clin Pharmacol 1991;31(4):362–71 75 Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency Antimicrob Agents Chemother 1984;25(2):201–4 Available from: http://www.ncbi nlm.nih.gov/pubmed/6370127 76 Nikolaidis P, Tourkantonis A. Effect of hemodialysis on ceftazidime pharmacokinetics Clin Nephrol 1985;24(3):142–6 Available from: http://www.ncbi nlm.nih.gov/pubmed/3899438 77 Kinowski JM, de la Coussaye JE, Bressolle F, Fabre D, Saissi G, Bouvet O, et al Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration Antimicrob Agents Chemother 1993;37(3):464–73 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8460915 78 Losno Garcia R, Santivanez V, Battilana CA. Single- dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis Chemotherapy 1988;34(4):261–6 79 Kroh UF, Lennartz H, Edwards DJ, Stoeckel K. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration J Clin Pharmacol 1996;36(12):1114–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9013367 80 Konishi K, Suzuki H, Hayashi M, Saruta T. Pharmacokinetics of cefuroxime axetil in patients with normal and impaired renal function J Antimicrob Chemother 1993;31(3):413–20 36 Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal… Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8486575 81 Weiss LG, Cars O, Danielson BG, Grahnen A, Wikstrom B. Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration Clin Nephrol 1988;30(5):282–6 82 Janssen PKC, Foudraine NA, Burgers DMT, Neef K, Le Noble JLML. Population pharmacokinetics of cefuroxime in critically ill patients receiving continuous venovenous hemofiltration with regional citrate anticoagulation and a phosphate-containing replacement fluid Ther Drug Monit 2016;38(6):699–705 83 Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP. Pharmacokinetics of ciprofloxacin tablets in renal failure; influence of haemodialysis Eur J Clin Pharmacol 1987;31(5):589–93 84 Roger C, Wallis SC, Louart B, Lefrant J-Y, Lipman J, Muller L, et al Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients J Antimicrob Chemother 2016;71(6):1643–50 85 Spooner AM, Deegan C, D’Arcy DM, Gowing CM, Donnelly MB, Corrigan OI. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration BMC Clin Pharmacol 2011;11:11 86 Roberts AP, Eastwood JB, Gower PE, Fenton CM, Curtis JR. Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects Eur J Clin Pharmacol 1978;14(6):435–9 87 Paap CM, Nahata MC. Clinical use of trimethoprim/ sulfamethoxazole during renal dysfunction DICP 1989;23(9):646–54 Available from: http://www ncbi.nlm.nih.gov/pubmed/2678767 88 Nissenson AR, Wilson C, Holazo A. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole during hemodialysis Am J Nephrol 1987;7(4):270–4 89 Kesner JM, Yardman-Frank JM, Mercier R-C, Wong CS, Walker SE, Argyres DP, et al Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy Blood Purif 2014;38(3–4):195–202 90 Curkovic I, Luthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration Ann Pharmacother 2010;44(10):1669–72 91 Walker SE, Paton TW, Churchill DN, Ojo B, Manuel MA, Wright N. Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis (CAPD) Perit Dial Int 1989;9(1):51–5 92 Disse B, Gundert-Remy U, Weber E, Andrassy K, Sietzen W, Lang A. Pharmacokinetics of erythromycin in patients with different degrees of renal 701 impairment Int J Clin Pharmacol Ther Toxicol 1986;24(9):460–4 93 Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir Clin Pharmacokinet 1996;31(1):1– Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8827396 94 Boike SC, Pue MA, Freed MI, Audet PR, Fairless A, Ilson BE, et al Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment Clin Pharmacol Ther 1994;55(4):418–26 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8162668 95 Dudley MN. Clinical pharmacology of fluconazole Pharmacotherapy 1990;10(6 (Pt 3)):141S– 5S. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/2075112 96 Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole Pharmacotherapy 2019;14(4):502–5 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/7937290 97 Patel K, Roberts JA, Lipman J, Tett SE, Deldot ME, Kirkpatrick CM. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets Antimicrob Agents Chemother 2011;55(12):5868–73 Available from: http://aac.asm.org/lookup/doi/10.1128/ AAC.00424-11 98 Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R, et al Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations J Acquir Immune Defic Syndr Hum Retrovirol 1999;20(4):350–7 99 Alexander AC, Akers A, Matzke GR, Aweeka FT, Fraley DS. Disposition of foscarnet during peritoneal dialysis Ann Pharmacother 1996;30(10):1106– Available from: http://journals.sagepub.com/ doi/10.1177/106002809603001007 100 Combarnous F, Fouque D, Bernard N, Boulieu R, Chossegros P, Laville M, et al Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis Eur J Clin Pharmacol 1994;46(4):379–81 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/7957527 101 Boulieu R, Bastien O, Bleyzac N. Pharmacokinetics of ganciclovir in heart transplant patients undergoing continuous venovenous hemodialysis Ther Drug Monit 1993;15(2):105–7 102 Horvatits T, Kitzberger R, Drolz A, Zauner C, Jäger W, Böhmdorfer M, et al Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients Antimicrob Agents Chemother 2014;58(1):94–101 Available from: http://aac.asm.org/lookup/doi/10.1128/ AAC.00892-13 702 103 Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration Crit Care Med 1998;26(1):184–7 104 Sommadossi JP, Bevan R, Ling T, Lee F, Mastre B, Chaplin MD, et al Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function Rev Infect Dis 2019;10(Suppl 3):S507–14 Available from: http://www.ncbi.nlm nih.gov/pubmed/2847287 105 Golper TA, Bennett WM. Drug removal by continuous arteriovenous haemofiltration A review of the evidence in poisoned patients Med Toxicol Adverse Drug Exp 1988;3(5):341–9 106 Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration Crit Care Med 1992;20(5):586–9 Available from: http:// www.ncbi.nlm.nih.gov/pubmed/1572182 107 Hamann SR, Oeltgen PR, Shank WA, Blouin RA, Natarajan L. Evaluation of gentamicin pharmacokinetics during peritoneal dialysis Ther Drug Monit 1982;4(3):297–300 Available from: http://www ncbi.nlm.nih.gov/pubmed/6753255 108 Somani P, Freimer EH, Gross ML, Higgins JTJ. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 1988;32(4):530–4 109 Verpooten GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure Br J Clin Pharmacol 1984;18(2):183–93 110 Tegeder I, Bremer F, Oelkers R, Schobel H, Schüttler J, Brune K, et al Pharmacokinetics of imipenem- cilastatin in critically ill patients undergoing continuous venovenous hemofiltration Antimicrob Agents Chemother 1997;41(12):2640–5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9420033 111 Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol Am J Respir Crit Care Med 1999;159(5 Pt 1):1580–4 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/10228130 112 Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment Nephron 1993;64(2):169– 81 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8321347 113 Ahn C, Oh K-H, Kim K, Lee KY, Lee JG, Oh MD, et al Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin Perit Dial Int 2019;23(4):362– Available from: http://www.ncbi.nlm.nih.gov/ pubmed/12968844 114 Gold CH, Buchanan N, Tringham V, Viljoen M, Strickwold B, Moodley GP. Isoniazid pharmacokinetics in patients in chronic renal failure Clin B L Blowey et al Nephrol 1976;6(2):365–9 Available from: http:// www.ncbi.nlm.nih.gov/pubmed/954244 115 Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole Clin Pharmacokinet 1988;14(1):13–34 Available from: http://www.ncbi nlm.nih.gov/pubmed/3280211 116 Therasse DG, Farlow DS, Davidson RL, Quadracci LJ, Hatcher BL, Cerimele BJ, et al Effects of renal dysfunction on the pharmacokinetics of loracarbef Clin Pharmacol Ther 1993;54(3):311–6 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8375126 117 Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration Clin Pharmacol Ther 1999;65(1):50–7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9951430 118 Giles LJ, Jennings AC, Thomson AH, Creed G, Beale RJ, McLuckie A. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration Crit Care Med 2000;28(3):632–7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10752806 119 Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease Antimicrob Agents Chemother 1993;37(2):229– 33 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/8452352 120 Thalhammer F, Hörl WH. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy Clin Pharmacokinet 2000;39(4):271– Available from: http://link.springer com/10.2165/00003088-200039040-00003 121 Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ. Metronidazole pharmacokinetics in patients with acute renal failure J Antimicrob Chemother 1984;13(2):183–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/6706889 122 Cassey JG, Clark DA, Merrick P, Jones B. Pharmacokinetics of metronidazole in patients undergoing peritoneal dialysis Antimicrob Agents Chemother 1983;24(6):950–1 Available from: http://www.ncbi.nlm.nih.gov/pubmed/6660863 123 Ruedy J. The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease Can Med Assoc J 1966;94(6):257–61 124 Conte JEJ. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis J Infect Dis 1991;163(1):169–75 125 Conte JE, Upton RA, Lin ET. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function J Infect Dis 1987;156(6):885–90 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/3680992 36 Drug Administration and Pharmacogenomics in Children Receiving Acute or Chronic Renal… 126 Thompson MI, Russo ME, Matsen JM, Atkin-Thor E. Piperacillin pharmacokinetics in subjects with chronic renal failure Antimicrob Agents Chemother 1981;156:885–90 127 Francke EL, Appel GB, Neu HC. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis Antimicrob Agents Chemother 1979;16(6):788–91 128 Debruyne D, Ryckelynck JP, Hurault De Ligny B, Moulin M. Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis J Pharm Sci 1990;79(2):99–102 129 Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, et al Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy Pharmacotherapy 2015;35(6):600–7 130 Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, et al Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis Antimicrob Agents Chemother 2002;46(5):1557–60 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11959598 131 Tamme K, Oselin K, Kipper K, Tasa T, Metsvaht T, Karjagin J, et al Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock Acta Anaesthesiol Scand 2016;60(2):230– 40 Available from: http://doi.wiley.com/10.1111/ aas.12629 132 Parry MF, Neu HC. Pharmacokinetics of ticarcillin in patients with abnormal renal function J Infect Dis 1976;133(1):46–9 Available from: http://www ncbi.nlm.nih.gov/pubmed/1107435 133 Wise R, Reeves DS, Parker AS. Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis Antimicrob Agents Chemother 1974;5(2):119–20 134 Lockwood WR, Bower JD. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients Antimicrob Agents Chemother 1973;3(1):125–9 135 Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients J Clin Pharmacol 1986;26(8):686–9 136 Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Tobramycin kinetics during continuous ambulatory peritoneal dialysis Clin Pharmacol Ther 1983;34(1):110–6 Available from: http://www.ncbi nlm.nih.gov/pubmed/6861432 137 Smiley ML, Murray A, de Miranda P. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster Adv Exp Med Biol 1996;394:33–9 138 Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, et al Valganciclovir dosing according to body surface area and renal function 703 in pediatric solid organ transplant recipients Am J Transplant 2009;9(3):636–43 Available from: http:// doi.wiley.com/10.1111/j.1600-6143.2008.02528.x 139 Izzedine H, Mercadal L, Aymard G, Launay- Vacher V, Martinez V, Issad B, et al Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study Am J Nephrol 2001;21(2):162–4 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/11359026 140 Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis Perit Dial Int 2007;27(1):79–85 141 Moffett BS, Morris J, Munoz F, Arikan AA. Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy Eur J Clin Pharmacol 2019;75(8):1089–97 Available from: http://link.springer.com/10.1007/ s00228-019-02664-7 142 Kandrotas RJ, Oles KS, Gal P, Love JM. Carbamazepine clearance in hemodialysis and hemoperfusion DICP 1989;23(2):137–40 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/2728503 143 Lee CS, Wang LH, Marbury TC, Bruni J, Perchalski RJ. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis Clin Toxicol 1980;17(3):429–38 Available from: http://www.ncbi.nlm.nih.gov/pubmed/7449356 144 Wong MO, Eldon MA, Keane WF, Türck D, Bockbrader HN, Underwood BA, et al Disposition of gabapentin in anuric subjects on hemodialysis J Clin Pharmacol 1995;35(6):622–6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/7665723 145 Fillastre JP, Taburet AM, Fialaire A, Etienne I, Bidault R, Singlas E. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis Drugs Exp Clin Res 1993;19(1):25–32 146 Garnett WR. Lamotrigine: pharmacokinetics J Child Neurol 1997;12(Suppl 1):S10–5 Available from: http://www.ncbi.nlm.nih.gov/pubmed/9429124 147 Asconapé JJ. Use of antiepileptic drugs in hepatic and renal disease Handb Clin Neurol 2014;119:417–32 Available from: https://linkinghub.elsevier.com/ retrieve/pii/B9780702040863000278 148 Nei SD, Wittwer ED, Kashani KB, Frazee EN. Levetiracetam pharmacokinetics in a patient receiving continuous venovenous hemofiltration and venoarterial extracorporeal membrane oxygenation Pharmacotherapy 2015;35(8):e127–30 Available from: http://doi.wiley.com/10.1002/phar.1615 149 Wieruszewski PM, Kashani KB, Rabinstein AA, Frazee E. Levetiracetam pharmacokinetics in a critically ill anephric patient on intermittent hemodialysis Neurocrit Care 2018;28(2):243–6 Available from: http://link.springer.com/10.1007/ s12028-017-0441-4 150 Bahte SK, Hiss M, Lichtinghagen R, Kielstein JT. A missed opportunity – consequences of unknown levetiracetam pharmacokinetics in a peritoneal 704 dialysis patient BMC Nephrol 2014;15(1):49 Available from: http://bmcnephrol.biomedcentral com/articles/10.1186/1471-2369-15-49 151 New AM, Nei SD, Kashani KB, Rabinstein AA, Frazee EN. Levetiracetam pharmacokinetics during continuous venovenous hemofiltration and acute liver dysfunction Neurocrit Care 2016;25(1):141– Available from: http://link.springer.com/10.1007/ s12028-016-0242-1 152 Company-Albir MJ, Ruíz-Ramos J, Solana Altabella A, Marqués-Miñana MR, Vicent C, Poveda JL. Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: case report J Clin Pharm Ther 2017;42(6):774–5 Available from: http://doi.wiley.com/10.1111/ jcpt.12568 153 Van Matre ET, Mueller SW, Fish DN, MacLaren R, Cava LF, Neumann RT, et al Levetiracetam pharmacokinetics in a patient with intracranial hemorrhage undergoing continuous veno-venous hemofiltration Am J Case Rep 2017;18:458–62 154 Porto I, John EG, Heilliczer J. Removal of phenobarbital during continuous cycling peritoneal dialysis in a child Pharmacotherapy 1997;17(4):832–5 155 Czajka PA, Anderson WH, Christoph RA, Banner W. A pharmacokinetic evaluation of peritoneal dialysis for phenytoin intoxication J Clin Pharmacol 1980;20(10):565–9 Available from: http://www ncbi.nlm.nih.gov/pubmed/7440764 156 Lapierre O, Dubreucq JL, Beauchemin MA, Vinet B. Valproic acid intoxication in a patient with bipolar disorder and chronic uremia Can J Psychiatry 1999;44(2):188 Available from: http://www.ncbi nlm.nih.gov/pubmed/10097841 157 Orr JM, Farrell K, Abbott FS, Ferguson S, Godolphin WJ. The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child Eur J Clin Pharmacol 1983;24(3):387–90 Available from: http://www.ncbi.nlm.nih.gov/pubmed/6407847 158 Ghannoum M, Laliberte M, Nolin TD, MacTier R, Lavergne V, Hoffman RS, et al Extracorporeal treatment for valproic acid poisoning: systematic review and recommendations from the EXTRIP workgroup Clin Toxicol (Phila) 2015;53(5):454–65 159 Thanacoody RH. Extracorporeal elimination in acute valproic acid poisoning Clin Toxicol (Phila) 2009;47(7):609–16 Available from: http://www.tandfonline.com/doi/ full/10.1080/15563650903167772 160 Khadzhynov D, Slowinski T, Lieker I, Neumayer H-H, Albrecht D, Streefkerk HJ, et al Pharmacokinetics of aliskiren in patients with end- stage renal disease undergoing haemodialysis Clin Pharmacokinet 2012;51(10):661–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23018529 161 Laher MS, Kelly JG, Doyle GD, Carmody M, Donohoe JF, Greb H, et al Pharmacokinetics of amlodipine in renal impairment J Cardiovasc Pharmacol B L Blowey et al 1988;12(Suppl 7):S60–3 Available from: http:// www.ncbi.nlm.nih.gov/pubmed/2467131 162 Doyle GD, Donohue J, Carmody M, Laher M, Greb H, Volz M. Pharmacokinetics of amlodipine in renal impairment Eur J Clin Pharmacol 1989;36(2):205– Available from: http://www.ncbi.nlm.nih.gov/ pubmed/2524389 163 Kungys G, Naujoks H, Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis Eur J Clin Pharmacol 2003;59(4):291–5 Available from: http://www.ncbi nlm.nih.gov/pubmed/12845505 164 Wan SH, Koda RT, Maronde RF. Pharmacokinetics, pharmacology of atenolol and effect of renal disease Br J Clin Pharmacol 1979;7(6):569–74 Available from: http://www.ncbi.nlm.nih.gov/pubmed/465278 165 Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis Br J Clin Pharmacol 1984;18(3):457–60 166 Flouvat B, Decourt S, Aubert P, Potaux L, Domart M, Goupil A, et al Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis Br J Clin Pharmacol 1980;9(4):379–85 167 Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL β-Blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial Clin J Am Soc Nephrol 2018;13(4):604–11 Available from: http://cjasn.asnjournals.org/lookup/doi/10.2215/ CJN.07470717 168 Ferguson RK, Rotmensch HH, Vlasses PH. Clinical use of captopril Illustrative cases JAMA 1982;247(15):2117–9 Available from: http://www ncbi.nlm.nih.gov/pubmed/7038176 169 Sica DA, Gehr TW, Fernandez A. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease Drug Saf 2000;22(5):350– 60 Available from: http://www.ncbi.nlm.nih.gov/ pubmed/10830252 170 Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y. Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis Nephron 1986;44(4):324–8 171 Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure Kidney Int 1984;25(6):942–7 Available from: http://www.ncbi nlm.nih.gov/pubmed/6381858 172 Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure Clin Pharmacokinet 1993;24(3):230–54 173 Lowenthal DT, Saris SD, Paran E, Cristal N. The use of transdermal clonidine in the hypertensive patient with chronic renal failure Clin Nephrol 1993;39(1):37–43 Available from: http://www.ncbi nlm.nih.gov/pubmed/8428406 ... modeled continuous renal replacement therapy Blood Purif 2014;38(3–4):195–202 90 Curkovic I, Luthi B, Franzen D, Ceschi A, Rudiger A, Corti N. Trimethoprim/Sulfamethoxazole pharmacokinetics... GA, Verbist L, Buntinx AP, Entwistle LA, Jones KH, De Broe ME. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects